Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
复制标题
DOI：
10.1016/j.trre.2007.09.003
复制
发表时间：
2008-01-01
期刊：
影响因子：
--
通讯作者：
Cruzado, Josep M
中科院分区：
文献类型：
--
作者：
Cruzado, Josep M
哺乳动物雷帕霉素靶蛋白（mTOR）整合了参与细胞生长的营养和激素信号。mTOR抑制剂药物作为主要人类疾病如肥胖症、糖尿病、动脉粥样硬化或癌症的治疗剂的开发将在未来几年内经历重要的增长。这些疾病的发病率在器官移植受者中尤其增加，成为移植成功的限制因素。移植团队在使用mTOR抑制剂治疗患者以预防急性排斥反应或减少肾毒性方面具有重要经验。初步数据显示，这些药物对减少移植后恶性肿瘤有效。移植团队有独特的机会来分析mTOR抑制剂是否也能有效预防心血管疾病、肥胖和糖尿病。
Mammalian target of rapamycin (mTOR) integrates nutrient and hormonal signals involved in cell growth. Development of mTOR inhibitor drugs as therapeutic agents for major human diseases such as obesity, diabetes, atherosclerosis, or cancer will experience an important increase in the next years. The incidence of these diseases is particularly increased among organ transplant recipients being a limiting factor for transplant success. Transplant teams carry on significant experience in treating patients with mTOR inhibitors for preventing acute rejection or reducing nephrotoxicity. Preliminary data showed that these drugs are effective for reducing posttransplant malignancy. Transplant teams have the unique opportunity to analyze whether mTOR inhibitors are also effective for the prevention of cardiovascular diseases, obesity, and diabetes.